Inclusion Criteria:

          -  Women with stages II-IV epithelial ovarian, fallopian tube, or primary peritoneal
             carcinoma who have completed standard therapy for primary or recurrent disease (i.e.,
             patients who would normally be observed); eligible patients may have asymptomatic
             residual measurable disease on physical examination and/or computed tomography (CT)
             scan, and/or may have an elevated cancer antigen 125 (CA-125); or may be in complete
             clinical remission after treatment for primary or recurrent disease; these patients
             would normally enter a period of observation after standard management

          -  Any human leukocyte antigen (HLA) type (historic HLA typing is permitted)

          -  Tumor expression of NY-ESO-1 by immunohistochemistry (IHC) and/or real-time polymerase
             chain reaction (RTPCR)

          -  No history of previous severe allergic reactions to vaccines or unknown allergens

          -  Life expectancy > 6 months

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

          -  Hematology and biochemistry laboratory results within the limits normally expected for
             the patient population, without evidence of major organ failure

          -  Absolute neutrophil count (ANC) >= 1,000/uL

          -  Platelets (PLT) >= 75,000/uL

          -  Hemoglobin (Hgb) >= 8 g/dL

          -  Total bilirubin =< 1.5 x upper limits of normal (ULN)

          -  Serum glutamic-oxaloacetic transaminase(SGOT)/aspartate aminotransferase (AST) or
             serum glutamate pyruvate transaminase(SGPT)/alanine aminotransferase (ALT) =< 3 x ULN

          -  Serum creatinine =< 2 x ULN

          -  Prothrombin time(PT)/international normalized ratio(INR) =< 1.5

          -  Electrocardiogram, showing no indications of cardiac problems like congestive heart
             failure, myocardial infarction, and cardiomyopathy

          -  Have been informed of other treatment options

          -  Ability to swallow and retain oral medication

          -  Participants of child-bearing potential must agree to use adequate contraceptive
             methods (e.g., hormonal or barrier method of birth control) prior to study entry;
             should a woman become pregnant or suspect she is pregnant while she is participating
             in this study, she should inform her treating physician immediately

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

          -  Patients may have received previous NY-ESO-1 vaccine therapy

        Exclusion Criteria:

          -  Metastatic disease to the central nervous system

          -  Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
             disorders)

          -  History of severe autoimmune disorders requiring use of steroids or other
             immunosuppressives

          -  Concomitant systemic treatment with corticosteroids, anti-histamine or non-steroidal
             antiinflammatory drugs for >2 weeks,, and other platelet inhibitory agents, strong
             inhibitors/inducers of cytochrome P450-3A4 (CYP450-3A4)

          -  Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing
             of study drug (6 weeks for nitrosoureas); concomitant hormonal therapies for breast
             cancers are allowed

          -  Patients with a positive fecal occult blood test excluding hemorrhoids

          -  Clinically significant heart disease (New York Heart Association [NYHA] class III or
             IV) within six months

          -  Participation in any other clinical trial involving another investigational agent
             within 4 weeks prior to first dosing of study drug

          -  Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)

          -  Mental impairment that may compromise the ability to give informed consent and comply
             with the requirements of the study

          -  Lack of availability of a patient for immunological and clinical follow-up assessment

          -  Known pulmonary hypertension

          -  Known hypersensitivity to sirolimus

          -  Evidence of current drug or alcohol abuse or psychiatric impairment, which in the
             Investigator's opinion will prevent completion of the protocol therapy or follow-up

          -  Pregnant or nursing female patients

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the patient an unsuitable
             candidate to receive study drug (i.e., any significant medical illness or abnormal
             laboratory finding that would, in the investigator's judgment, increase the subject's
             risk by participating in this study)